Crescentis Capital Ltd Receives In-Principle Approval for Employee Stock Options
Crescentis Capital Ltd has received in-principle approval from BSE Limited for the issuance of equity shares under its 'Crescentis Capital Limited Employees' Stock Option Scheme 2025'. The approval pertains to a maximum of 13,00,000 equity shares, each having a face value of ₹10/-.The in-principle approval was granted by BSE Limited via a letter referencing number DCS/ESOP/IP/RD/006/2026-27, dated April 02, 2026.
The issuance is tied to the exercise of stock options in accordance with the Securities Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
The approval is subject to Crescentis Capital Ltd fulfilling several conditions mandated by the Exchange. These conditions include:
- Notifying the Exchange according to the format prescribed under Regulation 10(c) of the Securities Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, after the shares are allotted and credited to the beneficiaries' accounts or share certificates are dispatched.
- Payment of prescribed fees when required.
- Receipt of statutory and other approvals, alongside compliance with guidelines issued by statutory authorities such as SEBI, RBI, and MCA.
- Compliance with all guidelines, regulations, and directions from the Exchange or any statutory authorities, as well as fulfilling documentary requirements.
- Adherence to all conditions stipulated in the Listing Agreement as of the listing date.
- Compliance with the Companies Act, 1956 / 2013 and other applicable laws.
- Submission of documents as outlined in the Checklist available on the BSE website.
The Company name is Crescentis Capital Ltd, formerly known as Som Datt Finance Corporation Limited.
The details of the approval and the involved shares are summarized below:
| Metric | Value |
|---|---|
| Total Shares Approved | 13,00,000 |
| Face Value Per Share | ₹10/- |
| Scheme Name | Crescentis Capital Limited Employees' Stock Option Scheme 2025 |
| Approval Letter Date | April 02, 2026 |
| Approval Reference No. | DCS/ESOP/IP/RD/006/2026-27 |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.